Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens

European Journal of Immunology

Volumn 41, Issue 2, 2011, Pages 345-355

  Iwasaki, Masashi ^a   Tanaka, Yoshimasa ^a   Kobayashi, Hirohito ^b   Murata Hirai, Kaoru ^a   Miyabe, Hideto ^c   Sugie, Tomoharu ^a   Toi, Masakazu ^a   Minato, Nagahiro ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

T cells; PD 1; PD L1; Phosphoantigen; Tumor

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; ZOLEDRONIC ACID;

ARTICLE; CELL ACTIVITY; CELL FUNCTION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DAUDI CELL; EFFECTOR CELL; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR CELL;

ANTIGENS; ANTIGENS, CD; ANTIGENS, SURFACE; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DIPHOSPHATES; DIPHOSPHONATES; HUMANS; IMIDAZOLES; INTERFERON-GAMMA; INTERLEUKIN-2; JURKAT CELLS; LYMPHOCYTE ACTIVATION; ORGANOPHOSPHORUS COMPOUNDS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES;

EID: 78851472436     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201040959     Document Type: Article

References (50)

1. Constant, P., Davodeau, F., Peyrat, M. A., Poquet, Y., Puzo, G., Bonneville, M. and Fournie, J. J., Stimulation of human γδ T cells by nonpeptidic mycobacterial ligands. Science 1994. 264: 267-270.
2. Tanaka, Y., Sano, S., Nieves, E., De Libero, G., Rosa, D., Modlin, R. L., Brenner, M. B. et al., Nonpeptide ligands for human γδ T cells. Proc. Natl. Acad. Sci. USA 1994. 91: 8175-8179.
3. Tanaka, Y., Morita, C. T., Nieves, E., Brenner, M. B. and Bloom, B. R., Natural and synthetic non-peptide antigens recognized by human γδ T cells. Nature 1995. 375: 155-158.
4. Chien, Y. H. and Bonneville, M., γδ T cell receptors. Cell Mol. Life Sci. 2006. 63: 2089-2094.
5. Hintz, M., Reichenberg, A., Altincicek, B., Bahr, U., Gschwind, R. M., Kollas, A. K., Beck, E. et al., Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human γδ T cells in Escherichia coli. FEBS Lett. 2001. 509: 317-322.
6. Rohdich, F., Hecht, S., Gartner, K., Adam, P., Krieger, C., Amslinger, S., Arigoni, D. et al., Studies on the nonmevalonate terpene biosynthetic pathway: metabolic role of IspH (LytB) protein. Proc. Natl. Acad. Sci. USA 2002. 99: 1158-1163.
7. Das, H., Wang, L., Kamath, A. and Bukowski, J. F., Vγ2Vδ2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 2001. 98: 1616-1618.
8. Kato, Y., Tanaka, Y., Miyagawa, F., Yamashita, S. and Minato, N., Targeting of tumor cells for human γδ T cells by nonpeptide antigens. J. Immunol. 2001. 167: 5092-5098.
9. van Beek, E., Pieterman, E., Cohen, L., Lowik, C. and Papapoulos, S., Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun. 1999. 264: 108-111.
10. Dunford, J. E., Thompson, K., Coxon, F. P., Luckman, S. P., Hahn, F. M., Poulter, C. D., Ebetino, F. H. and Rogers, M. J., Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 2001. 296: 235-242.
11. Gober, H. J., Kistowska, M., Angman, L., Jeno, P., Mori, L. and De Libero, G., Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 2003. 197: 163-168.
12. Morita, C. T., Jin, C., Sarikonda, G. and Wang, H., Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vγ2Vδ2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol. Rev. 2007. 215: 59-76.
13. Harwood, H. J. Jr., Alvarez, I. M., Noyes, W. D. and Stacpoole, P. W., In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma. J. Lipid Res. 1991. 32: 1237-1252.
14. Asslan, R., Pradines, A., Pratx, C., Allal, C., Favre, G. and Le Gaillard, F., Epidermal growth factor stimulates 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression via the ErbB-2 pathway in human breast adenocarcinoma cells. Biochem. Biophys. Res. Commun. 1999. 260: 699-706.
15. Hayday, A. C., γδ T cells and the lymphoid stress-surveillance response. Immunity 2009. 31: 184-196.
16. Bonneville, M. and Fournie, J. J., Sensing cell stress and transformation through Vγ9Vδ2 T cell-mediated recognition of the isoprenoid pathway metabolites. Microbes Infect. 2005. 7: 503-509.
17. Garcia, V. E., Sieling, P. A., Gong, J., Barnes, P. F., Uyemura, K., Tanaka, Y., Bloom, B. R. et al., Single-cell cytokine analysis of γδ T cell responses to nonpeptide mycobacterial antigens. J. Immunol. 1997. 159: 1328-1335.
18. Kabelitz, D., Effector functions and control of human γδ T-cell activation. Microbes Infect. 1999. 1: 255-261.
19. Bonneville, M. and Scotet, E., Human Vγ9Vδ2 T cells: promising new leads for immunotherapy of infections and tumors. Curr. Opin. Immunol. 2006. 18: 539-546.
20. Greenwald, R. J., Freeman, G. J. and Sharpe, A. H., The B7 family revisited. Annu. Rev. Immunol. 2005. 23: 515548.
21. Lin, D. Y., Tanaka, Y., Iwasaki, M., Gittis, A. G., Su, H. P., Mikami, B., Okazaki, T. et al., The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc. Natl. Acad. Sci. USA 2008. 105: 3011-3016.
22. Lazar-Molnar, E., Yan, Q., Cao, E., Ramagopal, U., Nathenson, S. G. and Almo, S. C., Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc. Natl. Acad. Sci. USA 2008. 105: 10448-10483.
23. Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J. et al., Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 2000. 192: 1027-1034.
24. Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y. et al., PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2001. 2: 261-268.
25. Ishida, M., Iwai, Y., Tanaka, Y., Okazaki, T., Freeman, G. J., Minato, N. and Honjo, T., Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol. Lett. 2002. 84: 57-62.
26. Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S. et al., Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001. 291: 319-322.
27. Okazaki, T., Tanaka, Y., Nishio, R., Mitsuiye, T., Mizoguchi, A., Wang, J., Ishida, M. et al., Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat. Med. 2003. 9: 1477-1483.
28. Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T. and Minato, N., Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 2002. 99: 12293-12297.
29. Terawaki, S., Tanaka, Y., Nagakura, T., Hayashi, T., Shibayama, S., Muroi, K., Okazaki, T. et al., Specific and high-affinity binding of tetramerized PD-L1 extracellular domain to PD-1-expressing cells: possible application to enhance T cell function. Int. Immunol. 2007. 19: 881-890.
30. Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, s R. et al., Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 2003. 9: 562-567.
31. Thompson, R. H., Kuntz, S. M., Leibovich, B. C., Dong, H., Lohse, C. M., Webster, W. S., Sengupta, S. et al., Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006. 66: 3381-3385.
32. + T-cell infiltration and survival of patients with cervical carcinoma. Clin. Cancer Res. 2009. 15: 6341-6347.
33. Wilcox, R. A., Feldman, A. L., Wada, D. A., Yang, Z. Z., Comfere, N. I., Dong, H., Kwon, E. D. et al., B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood 2009. 114: 2149-2158.
34. + T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. USA 2007.104: 3360-3365.
35. Chen, L., Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 2004. 4: 336-347.
36. Okazaki, T. and Honjo, T., PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 2007.19: 813-824.
37. Dong, H. and Chen, L., B7-H1 pathway and its role in the evasion of tumor immunity. J. Mol. Med. 2003. 81: 281-287.
38. Freeman, G. J., Wherry, E. J., Ahmed, R. and Sharpe, A. H., Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J. Exp. Med. 2006. 203: 2223-2227.
39. Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E. and Rosenberg, S. A., Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009.114: 1537-1544.
40. Kabelitz, D., Wesch, D. and He, W., Perspectives of γδ T cells in tumor immunology. Cancer Res. 2007. 67: 5-8.
41. Kabelitz, D., Wesch, D., Pitters, E. and Zoller, M., Potential of human γδ T lymphocytes for immunotherapy of cancer. Int. J. Cancer 2004. 112: 727-732.
42. Kunzmann, V., Bauer, E. and Wilhelm, M., γδ T-cell stimulation by pamidronate. N. Engl. J. Med. 1999. 340: 737-738.
43. Santini, D., Martini, F., Fratto, M. E., Galluzzo, S., Vincenzi, B., Agrati, C., Turchi, F. et al., In vivo effects of zoledronic acid on peripheral γδ T lymphocytes in early breast cancer patients. Cancer Immunol. Immunother. 2009. 58: 31-38.
44. Kunzmann, V., Bauer, E., Feurle, J., Weissinger, F., Tony, H. P. and Wilhelm, M., Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000. 96: 384-392.
45. Kobayashi, H., Tanaka, Y., Yagi, J., Osaka, Y., Nakazawa, H., Uchiyama, T., Minato, N. and Toma, H., Safety profile and anti-tumor effects of adoptive immunotherapy using γδ T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol. Immunother. 2007. 56: 469-476.
46. Dieli, F., Vermijlen, D., Fulfaro, F., Caccamo, N., Meraviglia, S., Cicero, G., Roberts, A. et al., Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 2007. 67: 7450-7457.
47. Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Postlberger, S., Menzel, C., Jakesz, R. et al., Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 2009. 360: 679-691.
48. Kobayashi, H., Tanaka, Y., Shimmura, H., Minato, N. and Tanabe, K., Complete remission of lung metastasis following adoptive immunotherapy using activated autologous γδ T-cells in a patient with renal cell carcinoma. Anticancer Res. 2010. 30: 575-579.
49. Kato, Y., Tanaka, Y., Tanaka, H., Yamashita, S. and Minato, N., Requirement of species-specific interactions for the activation of human γδ T cells by pamidronate. J. Immunol. 2003. 170: 3608-3613.
50. Bukowski, J. F., Morita, C. T., Tanaka, Y., Bloom, B. R., Brenner, M. B., and Band, H., Vγ2Vδ2 TCR-dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer. J. Immunol. 1995. 154: 998-1006.